Clopidogrel Resistance and its Impact on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention

نویسندگان

  • Farzad Kobarfard Department of Medical Chemistry, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Froozan Ahmadpour Department of Clinical Pharmacy, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Mohammad Haji Aghajani Department of Cardiology, Emam Hossein Teaching and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Mohammad Sistanizad Department of clinical pharmacy, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.|- Department of Clinical Pharmacy, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Naeime Zarepishe Department of Clinical Pharmacy, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Neda Kazeminia Department of Clinical Pharmacy, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Olia Safi Department of Clinical Pharmacy, Faculty of pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Seyedpouzhia Shojaei Department of Critical Care Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
چکیده

The aim of current study was evaluating the frequency of clopidogrel resistance and its impact on clinical outcome of patients in Iranian patients. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who received standard dosage of clopidogrel (Plavix®, Sanofi, France, 600 mg loading dose and 75 mg/day afterward) were recruited. Platelet aggregation was measured using light transmission aggregometer. The patients were categorized as responder (platelet aggregation less than 43%) and non-responder (platelet aggregation more than 43%). All patients were evaluated for major adverse cardio vascular events one month and 3 years after the angioplasty based on MACE criteria by phone contact. One hundred and five patients with average age of 60.30±12.2 years entered the study of whom 26 (24.76%) did not respond to clopidogrel. None of patients experienced cardiac events one month after PCI. Three years after PCI, data was collected from 55 (69.62%) and 10 (38.46%) subjects in responder and non-responder groups, respectively. MACE criteria was positive in 4 patients, 3 (5.45%) in responder and 1 (10%) in non-responder group (p= 0.28). We did not find any significant differences between clopidogrel resistance and past medical history. In drug history 1 (1.26%) and 4 (15.38%) patients received omeprazole with clopidogrel in responder and none-responder group, respectively (p= 0.003). This study showed 24.76% resistance to clopidogrel in Iranian population but, we did not find any correlation between clopidogrel resistance and cardiac events in follow up maybe due to study limitations particularly missed follow-up in non-responder patients.

برای دانلود باید عضویت طلایی داشته باشید

برای دسترسی به متن کامل این مقاله و 23 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous Coronary Intervention

Clopidogrel is an antiplatelet agent currently used for preventing stent thrombosis. Despite certain clinical benefits of clopidogrel in patients undergoing percutaneous coronary intervention (PCI), adequate antiplatelet effect has not been obtained in some patients. The present study was designed to investigate the potential association of ABCB1 (ATP-Binding Cassette, Subfamily B, member1) gen...

متن کامل

Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous Coronary Intervention

Clopidogrel is an antiplatelet agent currently used for preventing stent thrombosis. Despite certain clinical benefits of clopidogrel in patients undergoing percutaneous coronary intervention (PCI), adequate antiplatelet effect has not been obtained in some patients. The present study was designed to investigate the potential association of ABCB1 (ATP-Binding Cassette, Subfamily B, member1) gen...

متن کامل

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test.Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosage...

متن کامل

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test.Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosage...

متن کامل

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosag...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}

  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

دانلود متن کامل

برای دسترسی به متن کامل این مقاله و 23 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید


عنوان ژورنال:

دوره 17  شماره 3

صفحات  1099- 1104

تاریخ انتشار 2018-07-01

با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2022